Global Neurotransmitter Endogenous Regulation Platform Market Growth (Status and Outlook) 2025-2031

Product Code: 1484430

Industry: Service & Software

Published: Apr 19,2025

Pages: 109

Delivery Time: 2-3 business days

Global Neurotransmitter Endogenous Regulation Platform Market Growth (Status and Outlook) 2025-2031

Product Code: 1484430

Industry: Service & Software

Published: Apr 19,2025

Pages: 109

Delivery Time: 2-3 business days

Select A Format

Single User License

USD3660

Multi Users License

USD5490

Corporate Users License

USD7320

Buy Now

Add To Cart

Or More Options：

PDF Download

Sample Request

Custom Request

Provide market analysis and obtain sources of data reports

Description

The global Neurotransmitter Endogenous Regulation Platform market size is predicted to grow from US$ 1425 million in 2025 to US$ 2930 million in 2031; it is expected to grow at a CAGR of 12.8% from 2025 to 2031.

The neurotransmitter endogenous regulation platform is a system built on neuroscience and molecular biotechnology, which is used to regulate the synthesis, release, reuptake and metabolism of neurotransmitters in the body, thereby maintaining the functional balance of the nervous system. This platform usually combines technologies such as gene editing, small molecule intervention or targeted vectors to accurately regulate the endogenous levels of key neurotransmitters such as dopamine, glutamate, and 5-hydroxytryptamine, and is widely used in the study of the mechanisms of neuropsychiatric diseases and the development of individualized intervention strategies.

United States market for Neurotransmitter Endogenous Regulation Platform is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Neurotransmitter Endogenous Regulation Platform is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Neurotransmitter Endogenous Regulation Platform is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Neurotransmitter Endogenous Regulation Platform players cover Neurocrine Biosciences, Intra-Cellular Therapies, BrainsWay, BlackThorn Therapeutics, MindMed, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Neurotransmitter Endogenous Regulation Platform Industry Forecast” looks at past sales and reviews total world Neurotransmitter Endogenous Regulation Platform sales in 2024, providing a comprehensive analysis by region and market sector of projected Neurotransmitter Endogenous Regulation Platform sales for 2025 through 2031. With Neurotransmitter Endogenous Regulation Platform sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurotransmitter Endogenous Regulation Platform industry.

This Insight Report provides a comprehensive analysis of the global Neurotransmitter Endogenous Regulation Platform landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Neurotransmitter Endogenous Regulation Platform portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurotransmitter Endogenous Regulation Platform market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurotransmitter Endogenous Regulation Platform and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurotransmitter Endogenous Regulation Platform.

This report presents a comprehensive overview, market shares, and growth opportunities of Neurotransmitter Endogenous Regulation Platform market by product type, application, key players and key regions and countries.

Segmentation by Type:
    Chemical Molecular Regulation Platform
    Bioengineering Regulation Platform

Segmentation by Application:
    Hospital
    Clinic
    Others

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

    Neurocrine Biosciences
    Intra-Cellular Therapies
    BrainsWay
    BlackThorn Therapeutics
    MindMed
    Voyager Therapeutics
    COMPASS Pathways
    Neuroelectrics
    Cervel Therapeutics
    Axsome Therapeutics
    Atai Life Sciences
    Neumora Therapeutics
    Alto Neuroscience
    An Ranfei

Table Of Contents

1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
    1.8 Market Estimation Caveats

2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Neurotransmitter Endogenous Regulation Platform Market Size (2020-2031)
        2.1.2 Neurotransmitter Endogenous Regulation Platform Market Size CAGR by Region (2020 VS 2024 VS 2031)
        2.1.3 World Current & Future Analysis for Neurotransmitter Endogenous Regulation Platform by Country/Region (2020, 2024 & 2031)
    2.2 Neurotransmitter Endogenous Regulation Platform Segment by Type
        2.2.1 Chemical Molecular Regulation Platform
        2.2.2 Bioengineering Regulation Platform
    2.3 Neurotransmitter Endogenous Regulation Platform Market Size by Type
        2.3.1 Neurotransmitter Endogenous Regulation Platform Market Size CAGR by Type (2020 VS 2024 VS 2031)
        2.3.2 Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Type (2020-2025)
    2.4 Neurotransmitter Endogenous Regulation Platform Segment by Application
        2.4.1 Hospital
        2.4.2 Clinic
        2.4.3 Others
    2.5 Neurotransmitter Endogenous Regulation Platform Market Size by Application
        2.5.1 Neurotransmitter Endogenous Regulation Platform Market Size CAGR by Application (2020 VS 2024 VS 2031)
        2.5.2 Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Application (2020-2025)

3 Neurotransmitter Endogenous Regulation Platform Market Size by Player
    3.1 Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Player
        3.1.1 Global Neurotransmitter Endogenous Regulation Platform Revenue by Player (2020-2025)
        3.1.2 Global Neurotransmitter Endogenous Regulation Platform Revenue Market Share by Player (2020-2025)
    3.2 Global Neurotransmitter Endogenous Regulation Platform Key Players Head office and Products Offered
    3.3 Market Concentration Rate Analysis
        3.3.1 Competition Landscape Analysis
        3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
    3.4 New Products and Potential Entrants
    3.5 Mergers & Acquisitions, Expansion

4 Neurotransmitter Endogenous Regulation Platform by Region
    4.1 Neurotransmitter Endogenous Regulation Platform Market Size by Region (2020-2025)
    4.2 Global Neurotransmitter Endogenous Regulation Platform Annual Revenue by Country/Region (2020-2025)
    4.3 Americas Neurotransmitter Endogenous Regulation Platform Market Size Growth (2020-2025)
    4.4 APAC Neurotransmitter Endogenous Regulation Platform Market Size Growth (2020-2025)
    4.5 Europe Neurotransmitter Endogenous Regulation Platform Market Size Growth (2020-2025)
    4.6 Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size Growth (2020-2025)

5 Americas
    5.1 Americas Neurotransmitter Endogenous Regulation Platform Market Size by Country (2020-2025)
    5.2 Americas Neurotransmitter Endogenous Regulation Platform Market Size by Type (2020-2025)
    5.3 Americas Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2025)
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil

6 APAC
    6.1 APAC Neurotransmitter Endogenous Regulation Platform Market Size by Region (2020-2025)
    6.2 APAC Neurotransmitter Endogenous Regulation Platform Market Size by Type (2020-2025)
    6.3 APAC Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2025)
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia

7 Europe
    7.1 Europe Neurotransmitter Endogenous Regulation Platform Market Size by Country (2020-2025)
    7.2 Europe Neurotransmitter Endogenous Regulation Platform Market Size by Type (2020-2025)
    7.3 Europe Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2025)
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia

8 Middle East & Africa
    8.1 Middle East & Africa Neurotransmitter Endogenous Regulation Platform by Region (2020-2025)
    8.2 Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size by Type (2020-2025)
    8.3 Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2025)
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries

9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends

10 Global Neurotransmitter Endogenous Regulation Platform Market Forecast
    10.1 Global Neurotransmitter Endogenous Regulation Platform Forecast by Region (2026-2031)
        10.1.1 Global Neurotransmitter Endogenous Regulation Platform Forecast by Region (2026-2031)
        10.1.2 Americas Neurotransmitter Endogenous Regulation Platform Forecast
        10.1.3 APAC Neurotransmitter Endogenous Regulation Platform Forecast
        10.1.4 Europe Neurotransmitter Endogenous Regulation Platform Forecast
        10.1.5 Middle East & Africa Neurotransmitter Endogenous Regulation Platform Forecast
    10.2 Americas Neurotransmitter Endogenous Regulation Platform Forecast by Country (2026-2031)
        10.2.1 United States Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.2.2 Canada Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.2.3 Mexico Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.2.4 Brazil Market Neurotransmitter Endogenous Regulation Platform Forecast
    10.3 APAC Neurotransmitter Endogenous Regulation Platform Forecast by Region (2026-2031)
        10.3.1 China Neurotransmitter Endogenous Regulation Platform Market Forecast
        10.3.2 Japan Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.3.3 Korea Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.3.4 Southeast Asia Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.3.5 India Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.3.6 Australia Market Neurotransmitter Endogenous Regulation Platform Forecast
    10.4 Europe Neurotransmitter Endogenous Regulation Platform Forecast by Country (2026-2031)
        10.4.1 Germany Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.4.2 France Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.4.3 UK Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.4.4 Italy Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.4.5 Russia Market Neurotransmitter Endogenous Regulation Platform Forecast
    10.5 Middle East & Africa Neurotransmitter Endogenous Regulation Platform Forecast by Region (2026-2031)
        10.5.1 Egypt Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.5.2 South Africa Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.5.3 Israel Market Neurotransmitter Endogenous Regulation Platform Forecast
        10.5.4 Turkey Market Neurotransmitter Endogenous Regulation Platform Forecast
    10.6 Global Neurotransmitter Endogenous Regulation Platform Forecast by Type (2026-2031)
    10.7 Global Neurotransmitter Endogenous Regulation Platform Forecast by Application (2026-2031)
        10.7.1 GCC Countries Market Neurotransmitter Endogenous Regulation Platform Forecast

11 Key Players Analysis
    11.1 Neurocrine Biosciences
        11.1.1 Neurocrine Biosciences Company Information
        11.1.2 Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform Product Offered
        11.1.3 Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.1.4 Neurocrine Biosciences Main Business Overview
        11.1.5 Neurocrine Biosciences Latest Developments
    11.2 Intra-Cellular Therapies
        11.2.1 Intra-Cellular Therapies Company Information
        11.2.2 Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform Product Offered
        11.2.3 Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.2.4 Intra-Cellular Therapies Main Business Overview
        11.2.5 Intra-Cellular Therapies Latest Developments
    11.3 BrainsWay
        11.3.1 BrainsWay Company Information
        11.3.2 BrainsWay Neurotransmitter Endogenous Regulation Platform Product Offered
        11.3.3 BrainsWay Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.3.4 BrainsWay Main Business Overview
        11.3.5 BrainsWay Latest Developments
    11.4 BlackThorn Therapeutics
        11.4.1 BlackThorn Therapeutics Company Information
        11.4.2 BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Product Offered
        11.4.3 BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.4.4 BlackThorn Therapeutics Main Business Overview
        11.4.5 BlackThorn Therapeutics Latest Developments
    11.5 MindMed
        11.5.1 MindMed Company Information
        11.5.2 MindMed Neurotransmitter Endogenous Regulation Platform Product Offered
        11.5.3 MindMed Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.5.4 MindMed Main Business Overview
        11.5.5 MindMed Latest Developments
    11.6 Voyager Therapeutics
        11.6.1 Voyager Therapeutics Company Information
        11.6.2 Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Product Offered
        11.6.3 Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.6.4 Voyager Therapeutics Main Business Overview
        11.6.5 Voyager Therapeutics Latest Developments
    11.7 COMPASS Pathways
        11.7.1 COMPASS Pathways Company Information
        11.7.2 COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Product Offered
        11.7.3 COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.7.4 COMPASS Pathways Main Business Overview
        11.7.5 COMPASS Pathways Latest Developments
    11.8 Neuroelectrics
        11.8.1 Neuroelectrics Company Information
        11.8.2 Neuroelectrics Neurotransmitter Endogenous Regulation Platform Product Offered
        11.8.3 Neuroelectrics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.8.4 Neuroelectrics Main Business Overview
        11.8.5 Neuroelectrics Latest Developments
    11.9 Cervel Therapeutics
        11.9.1 Cervel Therapeutics Company Information
        11.9.2 Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Product Offered
        11.9.3 Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.9.4 Cervel Therapeutics Main Business Overview
        11.9.5 Cervel Therapeutics Latest Developments
    11.10 Axsome Therapeutics
        11.10.1 Axsome Therapeutics Company Information
        11.10.2 Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Product Offered
        11.10.3 Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.10.4 Axsome Therapeutics Main Business Overview
        11.10.5 Axsome Therapeutics Latest Developments
    11.11 Atai Life Sciences
        11.11.1 Atai Life Sciences Company Information
        11.11.2 Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Product Offered
        11.11.3 Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.11.4 Atai Life Sciences Main Business Overview
        11.11.5 Atai Life Sciences Latest Developments
    11.12 Neumora Therapeutics
        11.12.1 Neumora Therapeutics Company Information
        11.12.2 Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Product Offered
        11.12.3 Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.12.4 Neumora Therapeutics Main Business Overview
        11.12.5 Neumora Therapeutics Latest Developments
    11.13 Alto Neuroscience
        11.13.1 Alto Neuroscience Company Information
        11.13.2 Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Product Offered
        11.13.3 Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.13.4 Alto Neuroscience Main Business Overview
        11.13.5 Alto Neuroscience Latest Developments
    11.14 An Ranfei
        11.14.1 An Ranfei Company Information
        11.14.2 An Ranfei Neurotransmitter Endogenous Regulation Platform Product Offered
        11.14.3 An Ranfei Neurotransmitter Endogenous Regulation Platform Revenue, Gross Margin and Market Share (2020-2025)
        11.14.4 An Ranfei Main Business Overview
        11.14.5 An Ranfei Latest Developments

12 Research Findings and Conclusion

List Of Tables

List of Tables
 Table 1. Neurotransmitter Endogenous Regulation Platform Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
 Table 2. Neurotransmitter Endogenous Regulation Platform Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
 Table 3. Major Players of Chemical Molecular Regulation Platform
 Table 4. Major Players of Bioengineering Regulation Platform
 Table 5. Neurotransmitter Endogenous Regulation Platform Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
 Table 6. Global Neurotransmitter Endogenous Regulation Platform Market Size by Type (2020-2025) & ($ millions)
 Table 7. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Type (2020-2025)
 Table 8. Neurotransmitter Endogenous Regulation Platform Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
 Table 9. Global Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2025) & ($ millions)
 Table 10. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Application (2020-2025)
 Table 11. Global Neurotransmitter Endogenous Regulation Platform Revenue by Player (2020-2025) & ($ millions)
 Table 12. Global Neurotransmitter Endogenous Regulation Platform Revenue Market Share by Player (2020-2025)
 Table 13. Neurotransmitter Endogenous Regulation Platform Key Players Head office and Products Offered
 Table 14. Neurotransmitter Endogenous Regulation Platform Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
 Table 15. New Products and Potential Entrants
 Table 16. Mergers & Acquisitions, Expansion
 Table 17. Global Neurotransmitter Endogenous Regulation Platform Market Size by Region (2020-2025) & ($ millions)
 Table 18. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Region (2020-2025)
 Table 19. Global Neurotransmitter Endogenous Regulation Platform Revenue by Country/Region (2020-2025) & ($ millions)
 Table 20. Global Neurotransmitter Endogenous Regulation Platform Revenue Market Share by Country/Region (2020-2025)
 Table 21. Americas Neurotransmitter Endogenous Regulation Platform Market Size by Country (2020-2025) & ($ millions)
 Table 22. Americas Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Country (2020-2025)
 Table 23. Americas Neurotransmitter Endogenous Regulation Platform Market Size by Type (2020-2025) & ($ millions)
 Table 24. Americas Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Type (2020-2025)
 Table 25. Americas Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2025) & ($ millions)
 Table 26. Americas Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Application (2020-2025)
 Table 27. APAC Neurotransmitter Endogenous Regulation Platform Market Size by Region (2020-2025) & ($ millions)
 Table 28. APAC Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Region (2020-2025)
 Table 29. APAC Neurotransmitter Endogenous Regulation Platform Market Size by Type (2020-2025) & ($ millions)
 Table 30. APAC Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2025) & ($ millions)
 Table 31. Europe Neurotransmitter Endogenous Regulation Platform Market Size by Country (2020-2025) & ($ millions)
 Table 32. Europe Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Country (2020-2025)
 Table 33. Europe Neurotransmitter Endogenous Regulation Platform Market Size by Type (2020-2025) & ($ millions)
 Table 34. Europe Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2025) & ($ millions)
 Table 35. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size by Region (2020-2025) & ($ millions)
 Table 36. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size by Type (2020-2025) & ($ millions)
 Table 37. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size by Application (2020-2025) & ($ millions)
 Table 38. Key Market Drivers & Growth Opportunities of Neurotransmitter Endogenous Regulation Platform
 Table 39. Key Market Challenges & Risks of Neurotransmitter Endogenous Regulation Platform
 Table 40. Key Industry Trends of Neurotransmitter Endogenous Regulation Platform
 Table 41. Global Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Region (2026-2031) & ($ millions)
 Table 42. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share Forecast by Region (2026-2031)
 Table 43. Global Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Type (2026-2031) & ($ millions)
 Table 44. Global Neurotransmitter Endogenous Regulation Platform Market Size Forecast by Application (2026-2031) & ($ millions)
 Table 45. Neurocrine Biosciences Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 46. Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 47. Neurocrine Biosciences Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 48. Neurocrine Biosciences Main Business
 Table 49. Neurocrine Biosciences Latest Developments
 Table 50. Intra-Cellular Therapies Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 51. Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 52. Intra-Cellular Therapies Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 53. Intra-Cellular Therapies Main Business
 Table 54. Intra-Cellular Therapies Latest Developments
 Table 55. BrainsWay Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 56. BrainsWay Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 57. BrainsWay Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 58. BrainsWay Main Business
 Table 59. BrainsWay Latest Developments
 Table 60. BlackThorn Therapeutics Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 61. BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 62. BlackThorn Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 63. BlackThorn Therapeutics Main Business
 Table 64. BlackThorn Therapeutics Latest Developments
 Table 65. MindMed Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 66. MindMed Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 67. MindMed Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 68. MindMed Main Business
 Table 69. MindMed Latest Developments
 Table 70. Voyager Therapeutics Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 71. Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 72. Voyager Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 73. Voyager Therapeutics Main Business
 Table 74. Voyager Therapeutics Latest Developments
 Table 75. COMPASS Pathways Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 76. COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 77. COMPASS Pathways Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 78. COMPASS Pathways Main Business
 Table 79. COMPASS Pathways Latest Developments
 Table 80. Neuroelectrics Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 81. Neuroelectrics Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 82. Neuroelectrics Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 83. Neuroelectrics Main Business
 Table 84. Neuroelectrics Latest Developments
 Table 85. Cervel Therapeutics Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 86. Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 87. Cervel Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 88. Cervel Therapeutics Main Business
 Table 89. Cervel Therapeutics Latest Developments
 Table 90. Axsome Therapeutics Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 91. Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 92. Axsome Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 93. Axsome Therapeutics Main Business
 Table 94. Axsome Therapeutics Latest Developments
 Table 95. Atai Life Sciences Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 96. Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 97. Atai Life Sciences Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 98. Atai Life Sciences Main Business
 Table 99. Atai Life Sciences Latest Developments
 Table 100. Neumora Therapeutics Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 101. Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 102. Neumora Therapeutics Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 103. Neumora Therapeutics Main Business
 Table 104. Neumora Therapeutics Latest Developments
 Table 105. Alto Neuroscience Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 106. Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 107. Alto Neuroscience Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 108. Alto Neuroscience Main Business
 Table 109. Alto Neuroscience Latest Developments
 Table 110. An Ranfei Details, Company Type, Neurotransmitter Endogenous Regulation Platform Area Served and Its Competitors
 Table 111. An Ranfei Neurotransmitter Endogenous Regulation Platform Product Offered
 Table 112. An Ranfei Neurotransmitter Endogenous Regulation Platform Revenue ($ million), Gross Margin and Market Share (2020-2025)
 Table 113. An Ranfei Main Business
 Table 114. An Ranfei Latest Developments


List of Figures
 Figure 1. Neurotransmitter Endogenous Regulation Platform Report Years Considered
 Figure 2. Research Objectives
 Figure 3. Research Methodology
 Figure 4. Research Process and Data Source
 Figure 5. Global Neurotransmitter Endogenous Regulation Platform Market Size Growth Rate (2020-2031) ($ millions)
 Figure 6. Neurotransmitter Endogenous Regulation Platform Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
 Figure 7. Neurotransmitter Endogenous Regulation Platform Sales Market Share by Country/Region (2024)
 Figure 8. Neurotransmitter Endogenous Regulation Platform Sales Market Share by Country/Region (2020, 2024 & 2031)
 Figure 9. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Type in 2024
 Figure 10. Neurotransmitter Endogenous Regulation Platform in Hospital
 Figure 11. Global Neurotransmitter Endogenous Regulation Platform Market: Hospital (2020-2025) & ($ millions)
 Figure 12. Neurotransmitter Endogenous Regulation Platform in Clinic
 Figure 13. Global Neurotransmitter Endogenous Regulation Platform Market: Clinic (2020-2025) & ($ millions)
 Figure 14. Neurotransmitter Endogenous Regulation Platform in Others
 Figure 15. Global Neurotransmitter Endogenous Regulation Platform Market: Others (2020-2025) & ($ millions)
 Figure 16. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Application in 2024
 Figure 17. Global Neurotransmitter Endogenous Regulation Platform Revenue Market Share by Player in 2024
 Figure 18. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Region (2020-2025)
 Figure 19. Americas Neurotransmitter Endogenous Regulation Platform Market Size 2020-2025 ($ millions)
 Figure 20. APAC Neurotransmitter Endogenous Regulation Platform Market Size 2020-2025 ($ millions)
 Figure 21. Europe Neurotransmitter Endogenous Regulation Platform Market Size 2020-2025 ($ millions)
 Figure 22. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size 2020-2025 ($ millions)
 Figure 23. Americas Neurotransmitter Endogenous Regulation Platform Value Market Share by Country in 2024
 Figure 24. United States Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 25. Canada Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 26. Mexico Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 27. Brazil Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 28. APAC Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Region in 2024
 Figure 29. APAC Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Type (2020-2025)
 Figure 30. APAC Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Application (2020-2025)
 Figure 31. China Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 32. Japan Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 33. South Korea Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 34. Southeast Asia Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 35. India Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 36. Australia Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 37. Europe Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Country in 2024
 Figure 38. Europe Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Type (2020-2025)
 Figure 39. Europe Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Application (2020-2025)
 Figure 40. Germany Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 41. France Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 42. UK Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 43. Italy Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 44. Russia Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 45. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Region (2020-2025)
 Figure 46. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Type (2020-2025)
 Figure 47. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size Market Share by Application (2020-2025)
 Figure 48. Egypt Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 49. South Africa Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 50. Israel Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 51. Turkey Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 52. GCC Countries Neurotransmitter Endogenous Regulation Platform Market Size Growth 2020-2025 ($ millions)
 Figure 53. Americas Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 54. APAC Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 55. Europe Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 56. Middle East & Africa Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 57. United States Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 58. Canada Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 59. Mexico Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 60. Brazil Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 61. China Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 62. Japan Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 63. Korea Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 64. Southeast Asia Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 65. India Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 66. Australia Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 67. Germany Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 68. France Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 69. UK Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 70. Italy Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 71. Russia Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 72. Egypt Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 73. South Africa Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 74. Israel Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 75. Turkey Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)
 Figure 76. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share Forecast by Type (2026-2031)
 Figure 77. Global Neurotransmitter Endogenous Regulation Platform Market Size Market Share Forecast by Application (2026-2031)
 Figure 78. GCC Countries Neurotransmitter Endogenous Regulation Platform Market Size 2026-2031 ($ millions)

Companies Mentioned

Neurocrine Biosciences

Intra-Cellular Therapies

BrainsWay

BlackThorn Therapeutics

MindMed

Voyager Therapeutics

COMPASS Pathways

Neuroelectrics

Cervel Therapeutics

Axsome Therapeutics

Atai Life Sciences

Neumora Therapeutics

Alto Neuroscience

An Ranfei

Methodology

LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

Data Sourse

Primary Source

Secondary Source

Players/Suppliers

Journals and Periodicals

Industry Experts

Government Bodies

Distributors/Traders

Annual Reports

Opinion Leaders

Presentations

Front-line Staff